SYNGENE · NSE
Syngene International Limited
₹451.7
+3.28% (+₹14.35)
Prev. close
₹437.35
Volume
25,57,651
Delivery %
44.2%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommends buying Syngene International for intraday trading at ₹402, targeting ₹425, with a stop loss at ₹390.” | Vaishali ParekhPrabhudas Lilladher | Syngene International | MISS | |
| “Recommends buying Syngene above ₹658 with a stop loss at ₹650 and a target of ₹669. This is an intraday trade, suggestin…” | Raja VenkatramanNeoTrader | Syngene International Ltd | MISS | |
| “Bullish on SYNGENE, recommending an intraday buy above ₹661 with a target of ₹685 and a stop loss at ₹648. The stock has…” | Raja VenkatramanNeoTrader | Syngene International Ltd | MISS | |
| “Bullish on Syngene International Ltd, recommending to buy at current market price and on dips to ₹640, with a stop loss …” | Raja VenkatramanNeoTrader | Syngene International Ltd | MISS | |
| “Bullish on Syngene International, recommending to buy at current market price and on dips to ₹640, with a stop loss at ₹…” | Raja VenkatramanNeoTrader | Syngene International Ltd | MISS | |
| “Bullish on Syngene, which gave a consolidation breakout on July 17 and has sustained above its 20-day EMA, indicating st…” | Vatsal BhuvaLKP Securities | Syngene International Ltd | MISS | |
| “Bullish on Syngene International Ltd, recommending a buy at ₹681.10 with a near-term target of ₹720. The stock is showin…” | Ankush BajajIndependent | Syngene International Ltd | HIT | |
| “Recommends buying Syngene International in the short term, as it formed a bullish continuation pattern after consolidati…” | Prashanth TapseMehta Equities Ltd | Syngene International | HIT | |
| “Recommends buying Syngene International at ₹735, targeting ₹760, with a stop loss at ₹720.” | Vaishali ParekhPrabhudas Lilladher | Syngene International | MISS | |
| “Bullish on Syngene International with a target price of ₹960 for the next one year. The company is witnessing decent rev…” | Pankaj PandeyICICI Securities | Syngene International | MISS | |
| “Bullish on Syngene International with an 'outperform' rating and a target price of ₹835, implying a 19.2% upside. The co…” | Macquarie AnalysisMacquarie Capital Securities | Syngene International Ltd | MISS | |
| “Recommends selling Syngene International Ltd. at ₹830.50, targeting ₹790 with a stop loss at ₹855, within a timeframe of…” | Nagaraj ShettiHDFC Securities | Syngene International Ltd. | HIT | |
| “Bullish on Syngene International for the short-term, recommending a buy with a target price of Rs 886 and a stop loss at…” | Kunal BothraIndependent | Syngene International | MISS |
Market commentary · 2 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Syngene International, anticipating a sharp bounce if the stock sustains above ₹690, which would confirm a br…” | Anshul JainLakshmishree | Syngene International Ltd | — | |
| “Syngene International faces lower risk from potential US tariffs, with 68% US sales. The company primarily operates on a…” | Jefferies AnalysisJefferies | Syngene International Ltd | — |
Fundamentals
About Syngene International Limited
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Siddharth Mittal BCom, CA, CPA
Headquarters
Bengaluru
Employees
6,692
Website
syngeneintl.comExchange
View on NSE ↗Key stats
Market cap
₹16,779.89 Cr
P/E ratio (TTM)
90.4
Dividend yield
0.31%
EPS (TTM)
₹4.62
Beta (1Y · daily vs NIFTY 50)
0.69
Beta (5Y · monthly vs NIFTY 50)
1.20
Shares float
17.60 Cr
EPS · quarter ended Sept 2026
₹0.80
Upcoming earnings
20 Jan 2027
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,184.30 Cr | ₹2,604.20 Cr | ₹3,192.90 Cr | ₹3,488.60 Cr | ₹3,642.40 Cr | ₹3,738.70 Cr | |
EBITDA | ₹771.40 Cr | ₹818.20 Cr | ₹1,005.30 Cr | ₹1,093.90 Cr | ₹1,145.60 Cr | ₹912.60 Cr |
| ₹404.90 Cr | ₹395.80 Cr | ₹464.40 Cr | ₹510.00 Cr | ₹496.20 Cr | ₹316.70 Cr | |
Diluted EPS | ₹10.11 | ₹9.82 | ₹11.51 | ₹12.69 | ₹12.34 | ₹7.87 |
EBITDA for Mar 2021 could not be checked against the company's own annual report: this page shows ₹771.40 Cr while the annual report gives ₹736.40 Cr (4.5% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹699.50 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹5,831.00 Cr | ₹6,151.60 Cr | ₹6,795.90 Cr | ₹7,054.70 Cr | |
| — | — | ₹815.20 Cr | ₹555.20 Cr | ₹577.90 Cr | ₹458.40 Cr | |
Stockholders' equity | — | — | ₹3,618.00 Cr | ₹4,257.70 Cr | ₹4,726.80 Cr | ₹4,839.10 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹701.20 Cr | ₹580.60 Cr | ₹823.50 Cr | ₹1,042.10 Cr | ₹1,167.60 Cr | ₹915.20 Cr | |
Investing cash flow | ₹-628.10 Cr | ₹-611.50 Cr | ₹-656.40 Cr | ₹-495.60 Cr | ₹-744.70 Cr | ₹-860.40 Cr |
| ₹58.00 Cr | ₹-31.30 Cr | ₹-342.50 Cr | ₹-551.40 Cr | ₹-141.80 Cr | ₹-215.00 Cr | |
Capital expenditure | ₹-446.50 Cr | ₹-475.50 Cr | ₹-518.30 Cr | ₹-510.80 Cr | ₹-770.10 Cr | ₹-368.20 Cr |
End cash position | ₹323.30 Cr | ₹261.80 Cr | ₹89.50 Cr | ₹85.70 Cr | ₹367.10 Cr | ₹228.60 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24–Mar 25(2Q) | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.42% | 70.41% | 70.41% | 70.29% | 64.86% | 64.86% | 54.88% | 54.80% | 54.79% | 54.79% | 54.79% | 54.72% | 54.72% | 52.74% | 52.68% | 52.68% | 52.68% | 52.68% | 52.59% |
| Public | 28.72% | 28.87% | 28.91% | 28.89% | 34.65% | 34.67% | 44.66% | 44.60% | 44.72% | 44.89% | 44.90% | 44.85% | 44.94% | 46.97% | 47.00% | 47.01% | 47.02% | 47.03% | 46.98% |
| Employee trusts | 0.86% | 0.72% | 0.68% | 0.83% | 0.49% | 0.47% | 0.46% | 0.60% | 0.48% | 0.32% | 0.31% | 0.43% | 0.34% | 0.29% | 0.31% | 0.30% | 0.29% | 0.29% | 0.43% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Syngene International Limited | ₹16,341.81 Cr | ₹417.5 | 88.0 | 3.38 | 6.5% | 0.09 | +2.8% | -35.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.